Karthik Venkatakrishnan, Fcp

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9115474/publications.pdf

Version: 2024-02-01

63	1,174	430754	434063
papers	citations	18 h-index	31 g-index

63	63	63	1437
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Asiaâ€inclusive Clinical Research and Development Enabled by Translational Science and Quantitative Clinical Pharmacology: Toward a Culture That Challenges the Status Quo. Clinical Pharmacology and Therapeutics, 2023, 113, 298-309.	2.3	7
2	Essential (and Largely Untaught) Skills for Clinical Pharmacology in Oncology Drug Development. Clinical Pharmacology and Therapeutics, 2022, 111, 354-357.	2.3	0
3	Diversity and Inclusion in Drug Development: Rethinking Intrinsic and Extrinsic Factors with Patient Centricity. Clinical Pharmacology and Therapeutics, 2022, 112, 204-207.	2.3	11
4	Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 333-347.	1.3	14
5	Population pharmacokinetic and exposureâ€response analyses from ALTAâ€1L: Modelâ€based analyses supporting the brigatinib dose in ALKâ€positive NSCLC. Clinical and Translational Science, 2022, 15, 1143-1154.	1.5	7
6	Pharmacometrics Golems: Exposureâ€Response Models in Oncology. Clinical Pharmacology and Therapeutics, 2022, 112, 941-945.	2.3	6
7	Metabolism and Disposition of [¹⁴C]Pevonedistat, a First-In-Class NEDD8â€Activating Enzyme Inhibitor, After Intravenous Infusion to Patients With Advanced Solid Tumors . Drug Metabolism and Disposition, 2022, , DMD-AR-2022-000842.	1.7	1
8	Quantitative Clinical Pharmacology of CAR Tâ€Cell Therapy. Clinical Pharmacology and Therapeutics, 2022, 112, 11-15.	2.3	2
9	Physiologicallyâ€Based Pharmacokinetic Models as Enablers of Precision Dosing in Drug Development: Pivotal Role of the Human Mass Balance Study. Clinical Pharmacology and Therapeutics, 2021, 109, 51-54.	2.3	14
10	Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. Investigational New Drugs, 2021, 39, 488-498.	1.2	15
11	Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer. Clinical Pharmacokinetics, 2021, 60, 235-247.	1.6	15
12	Asiaâ€inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial. Clinical and Translational Science, 2021, 14, 1069-1081.	1.5	9
13	Effect of severe renal impairment on the pharmacokinetics of brigatinib. Investigational New Drugs, 2021, 39, 1306-1314.	1.2	7
14	Application of Machine Learning in Translational Medicine: Current Status and Future Opportunities. AAPS Journal, 2021, 23, 74.	2.2	35
15	Population Pharmacokinetics and Exposureâ€Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies. Journal of Clinical Pharmacology, 2021, , .	1.0	3
16	Modelâ€Informed Drug Development: Connecting the Dots With a Totality of Evidence Mindset to Advance Therapeutics. Clinical Pharmacology and Therapeutics, 2021, 110, 1147-1154.	2.3	10
17	Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. Clinical Pharmacology in Drug Development, 2020, 9, 214-223.	0.8	19
18	Toward Progress in Quantitative Translational Medicine: A Call to Action. Clinical Pharmacology and Therapeutics, 2020, 107, 85-88.	2.3	7

#	Article	IF	Citations
19	Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Modelâ€Informed Hypothesis Generation for Pediatric Dosing Regimens. Journal of Clinical Pharmacology, 2020, 60, 1585-1597.	1.0	3
20	Role of Physiologically Based Pharmacokinetic Modeling and Simulation in Enabling Modelâ€Informed Development of Drugs and Biotherapeutics. Journal of Clinical Pharmacology, 2020, 60, S7-S11.	1.0	4
21	Brigatinib Dose Rationale in Anaplastic Lymphoma Kinaseâ€"Positive Nonâ€Small Cell Lung Cancer: Exposureâ€"Response Analyses of Pivotal ALTA Study. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 718-730.	1.3	15
22	The Changing Face of Oncology Research, Drug Development, and Clinical Practice: Toward Patientâ€Focused Precision Therapeutics. Clinical Pharmacology and Therapeutics, 2020, 108, 399-404.	2.3	3
23	Biotransformation Pathways and Metabolite Profiles of Oral [14C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. Drug Metabolism and Disposition, 2020, 48, 217-229.	1.7	11
24	Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC. Journal of Thoracic Oncology, 2020, 15, 1190-1199.	0.5	23
25	Quantitative Translation in Immunoâ€Oncology Research and Development. Clinical Pharmacology and Therapeutics, 2020, 108, 430-433.	2.3	2
26	Staying Engaged in Your Career Without Burning Out: A Call for Action to Build Resilience. Clinical and Translational Science, 2020, 13, 1019-1022.	1.5	2
27	Challenges in Drug Development Posed by the COVIDâ€19 Pandemic: An Opportunity for Clinical Pharmacology. Clinical Pharmacology and Therapeutics, 2020, 108, 699-702.	2.3	17
28	A Translational Physiologically Based Pharmacokinetics/Pharmacodynamics Framework of Target-Mediated Disposition, Target Inhibition and Drugâ€"Drug Interactions of Bortezomib. AAPS Journal, 2020, 22, 66.	2.2	1
29	Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies. British Journal of Clinical Pharmacology, 2019, 85, 2568-2579.	1.1	13
30	Dose Optimization for Anticancer Drug Combinations: Maximizing Therapeutic Index via Clinical Exposure-Toxicity/Preclinical Exposure-Efficacy Modeling. Clinical Cancer Research, 2019, 25, 6633-6643.	3.2	18
31	Population Pharmacokinetic Modeling and Exposureâ€"Response Assessment for the Antibodyâ€Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELONâ€1 Study. Clinical Pharmacology and Therapeutics, 2019, 106, 1268-1279.	2.3	12
32	Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction. Journal of Clinical Pharmacology, 2019, 59, 1204-1215.	1.0	3
33	Come Dance With Me: Transformative Changes in theÂScience and Practice of Drugâ€"Drug Interactions. Clinical Pharmacology and Therapeutics, 2019, 105, 1272-1278.	2.3	8
34	Modelâ€Based Metaâ€Analysis: Optimizing Research, Development, and Utilization of Therapeutics Using the Totality of Evidence. Clinical Pharmacology and Therapeutics, 2019, 106, 981-992.	2.3	30
35	Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours. British Journal of Clinical Pharmacology, 2019, 85, 1464-1473.	1.1	9
36	Randomized Phase III Study of Alisertib or Investigatorâ€™s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. Journal of Clinical Oncology, 2019, 37, 613-623.	0.8	91

#	Article	IF	Citations
37	The Effect of a Highâ€Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. Clinical Pharmacology in Drug Development, 2019, 8, 734-741.	0.8	19
38	Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors. Investigational New Drugs, 2019, 37, 666-673.	1.2	5
39	Modelâ€Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor. Clinical Pharmacology and Therapeutics, 2019, 105, 376-387.	2.3	7
40	Reverse Translation: The Art of Cyclical Learning. Clinical Pharmacology and Therapeutics, 2018, 103, 152-159.	2.3	4
41	Population PK and Exposureâ€“Response Relationships for the Antibodyâ€“Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study. Clinical Pharmacology and Therapeutics, 2018, 104, 989-999.	2.3	20
42	Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011â€“2017: Lessons Learned for Anticancer Drug Development. Clinical and Translational Science, 2018, 11, 123-146.	1.5	36
43	Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia. British Journal of Clinical Pharmacology, 2018, 84, 35-51.	1.1	13
44	Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies. Investigational New Drugs, 2018, 36, 240-247.	1.2	5
45	Driving Access to Medicines With a Totality of Evidence Mindset: An Opportunity for Clinical Pharmacology. Clinical Pharmacology and Therapeutics, 2018, 103, 373-375.	2.3	24
46	Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. Clinical Cancer Research, 2018, 24, 6150-6159.	3.2	27
47	Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range. Journal of Clinical Pharmacology, 2017, 57, 1183-1193.	1.0	15
48	Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. Targeted Oncology, 2017, 12, 643-654.	1.7	19
49	Exposureâ€“safetyâ€“efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study. Investigational New Drugs, 2016, 34, 338-346.	1.2	19
50	Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. Drugs in R and D, 2016, 16, 45-52.	1.1	10
51	Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposureâ€“safety relationships. Journal of Clinical Pharmacology, 2015, 55, 336-347.	1.0	27
52	Switching from body surface areaâ€based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. British Journal of Clinical Pharmacology, 2015, 79, 789-800.	1.1	50
53	Pharmacokinetics and safety of ixazomib plus lenalidomideâ€“dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. Journal of Hematology and Oncology, 2015, 8, 103.	6.9	37
54	Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. Investigational New Drugs, 2015, 33, 942-953.	1.2	27

#	Article	IF	Citations
55	Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment. British Journal of Clinical Pharmacology, 2014, 77, 998-1010.	1.1	24
56	Translational Exposureâ€“Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib). Molecular Cancer Therapeutics, 2014, 13, 2170-2183.	1.9	29
57	Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment. British Journal of Clinical Pharmacology, 2014, 77, 986-997.	1.1	17
58	Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2012, 18, 4764-4774.	3.2	132
59	Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations. Clinical Cancer Research, 2012, 18, 4775-4784.	3.2	141
60	A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers. European Journal of Clinical Pharmacology, 2012, 68, 1347-1355.	0.8	14
61	Clinical pharmacologic considerations for the phase II/III dose/regimen of the investigational AuroraÂA kinase (AAK) inhibitor MLN8237 (alisertib): Pharmacokinetics (PK), pharmacodynamics (PD), and exposure-safety relationships.. Journal of Clinical Oncology, 2012, 30, 2597-2597.	0.8	0
62	Flat-Dosing Versus BSA-Based Dosing for MLN9708, An Investigational Proteasome Inhibitor: Population Pharmacokinetic (PK) Analysis of Pooled Data From 4 Phase-1 Studies. Blood, 2011, 118, 1433-1433.	0.6	6
63	Pharmacokinetics and Safety of Bortezomib In Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Results of the Phase 1 National Cancer Institute Organ Dysfunction Working Group Study NCI 6432. Blood, 2010, 116, 3975-3975.	0.6	0